Anna Solini
About
Anna Solini is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Molecular Biology.
According to data from OpenAlex, Anna Solini has authored 233 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Endocrinology, Diabetes and Metabolism, 67 papers in Cardiology and Cardiovascular Medicine and 54 papers in Molecular Biology. Recurrent topics in Anna Solini's work include Diabetes Treatment and Management (51 papers), Chronic Kidney Disease and Diabetes (35 papers) and Blood Pressure and Hypertension Studies (31 papers). Anna Solini is often cited by papers focused on Diabetes Treatment and Management (51 papers), Chronic Kidney Disease and Diabetes (35 papers) and Blood Pressure and Hypertension Studies (31 papers). Anna Solini collaborates with scholars based in Italy, United States and United Kingdom. Anna Solini's co-authors include Ele Ferrannini, Chiara Rossi, Enzo Bonora, Giuseppe Pugliese, Francesco Di Virgilio, Giuseppe Penno, E. Santini, Eleonora Santini, Emanuela Orsi and Cecilia Fondelli and has published in prestigious journals such as Journal of Clinical Investigation, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Anna Solini
228 papers receiving 7.2k citations
Hit Papers
Peers
Anna Solini
Shu Wakino Japan
Takashi Uzu Japan
Giuseppe Pugliese Italy
Shin‐ichi Araki Japan
Berthold Hocher Germany
Lars Christian Rump Germany
Markus Tölle Germany
Luís Henrique Santos Canani Brazil
Trond Jenssen Norway
Bong Soo South Korea
Citations per year, relative to Anna Solini Anna Solini (= 1×)
peers
Shu Wakino
Countries citing papers authored by Anna Solini
Since
Specialization
Citations
This map shows the geographic impact of Anna Solini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Solini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Solini more than expected).
Fields of papers citing papers by Anna Solini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anna Solini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Solini. The network helps show where Anna Solini may publish in the future.
Co-authorship network of co-authors of Anna Solini
This figure shows the co-authorship network connecting the top 25 collaborators of Anna Solini. A scholar is included among the top collaborators of Anna Solini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Solini. Anna Solini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Arca, Marcello, et al.. (2025). Challenges in achieving LDL-C goals: Insights from the Italian SANTORINI study cohort. Nutrition Metabolism and Cardiovascular Diseases. 36(2). 104412–104412.
2.
Rovera, Chiara, Diego Moriconi, Chiara Rossi, et al.. (2025). Effect of bempedoic acid on incretin axis and systemic and liver inflammation: a pilot, monocentric study. Nutrition Metabolism and Cardiovascular Diseases. 36(2). 104373–104373.
3.
Ciardullo, Stefano, Mario Luca Morieri, Teresa Vanessa Fiorentino, et al.. (2024). GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetologica. 61(8). 941–950.
4.
Garofolo, Monia, Martina Vitale, Giuseppe Penno, et al.. (2024). Prognostic impact of switching to the 2021 chronic kidney disease epidemiology collaboration creatinine-based equation in Caucasian patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study. Cardiovascular Diabetology. 23(1). 377–377.
5.
Fadini, Gian Paolo, Enrico Longato, Mario Luca Morieri, et al.. (2024). Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia. 67(11). 2585–2597.
6.
Arca, Marcello, Paolo Calabrò, Anna Solini, et al.. (2023). Lipid-lowering treatment and LDL-C goal attainment in high and very high cardiovascular risk patients: Evidence from the SANTORINI study-The Italian experience. CINECA IRIS Institutial research information system (University of Pisa). 2(1). 1–1.
7.
Anastasiou, Ioanna A., Niina Koivuviita, Kanishka Sharma, et al.. (2023). Renal Perfusion, Oxygenation and Metabolism: The Role of Imaging. Journal of Clinical Medicine. 12(15). 5141–5141.
8.
Rossi, Chiara, A Salvati, Daniela Campani, et al.. (2022). The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage. International Journal of Molecular Sciences. 23(13). 7447–7447.
9.
Bocci, Guido, Paola Orlandi, Maria Laura Manca, et al.. (2022). Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases. Journal of Clinical Medicine. 11(20). 5985–5985.
10.
Raggi, Francesco, et al.. (2022). P2X7 Receptor and Heart Function in a Mouse Model of Systemic Inflammation Due to High Fat Diet. Journal of Inflammation Research. Volume 15. 2425–2439.
11.
Orlandi, Paola, Anna Solini, Maurizia Rossana Brunetto, et al.. (2021). Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals. 14(10). 995–995.
12.
Bianchi, Cristina, Francesco Raggi, Chiara Rossi, et al.. (2021). MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance.. Diabetes & Metabolism. 48(2). 101292–101292.
13.
Solini, Anna, Chiara Rossi, Edoardo Biancalana, et al.. (2021). Molecular Characterization of Peritoneal Involvement in Primary Colon and Ovary Neoplasm: The Possible Clinical Meaning of the P2X7 Receptor-Inflammasome Complex. European Surgical Research. 63(3). 114–122.
14.
Suvan, Jeanie, Stefano Masi, Zoë Harrington, et al.. (2020). Effect of Treatment of Periodontitis on Incretin Axis in Obese and Nonobese Individuals: A Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 106(1). e74–e82.
15.
Orsi, Emanuela, Enzo Bonora, Anna Solini, et al.. (2020). Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. Journal of Clinical Medicine. 9(1). 246–246.
16.
Faita, Francesco, Nicole Di Lascio, Chiara Rossi, Claudia Kusmic, & Anna Solini. (2018). Ultrasonographic Characterization of thedb/dbMouse: An Animal Model of Metabolic Abnormalities. Journal of Diabetes Research. 2018. 1–9.
17.
Fantauzzi, Claudia Blasetti, Stefano Menini, Carla Iacobini, et al.. (2017). Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High‐Fat Diet: Possible Role of the NLRP3 Inflammasome. Oxidative Medicine and Cellular Longevity. 2017(1). 8962458–8962458.
18.
Pugliese, Giuseppe, Anna Solini, Enzo Bonora, et al.. (2014). Chronic kidney disease in type 2 diabetes: Lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutrition Metabolism and Cardiovascular Diseases. 24(8). 815–822.
19.
Solini, Anna, Andrea Carraro, Isabella Barzon, & Gaetano Crepaldi. (1994). Therapy with glycosaminoglycans lowers albumin excretion rate in non insulin dependent diabetic patients with macroalbuminuria. CINECA IRIS Institutial research information system (University of Pisa). 7(5). 304–307.
20.
Ghirlanda, Giovanni, et al.. (1987). Hypertension and dyslipidemia: captopril therapy and twelve months' follow-up. Current Therapeutic Research. 42(5). 948–953.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shu Wakino Breakdown of academic impact, for papers by Takashi Uzu Breakdown of academic impact, for papers by Giuseppe Pugliese Breakdown of academic impact, for papers by Shin‐ichi Araki Breakdown of academic impact, for papers by Berthold Hocher Breakdown of academic impact, for papers by Lars Christian Rump Breakdown of academic impact, for papers by Markus Tölle Breakdown of academic impact, for papers by Luís Henrique Santos Canani Breakdown of academic impact, for papers by Trond Jenssen Breakdown of academic impact, for papers by Bong Soo